Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
about
Interventions for skin reactions associated with targeted anticancer treatmentsInterventions for skin reactions associated with targeted anticancer treatmentsOral targeted therapy for cancerCutaneous adverse reactions specific to epidermal growth factor receptor inhibitorsCutaneous complications of molecular targeted therapy used in oncologyAcneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New InsightsNeutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptorDermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.Targeting the EGFR signaling pathway in cancer therapy.The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers.Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Management of egfr tki-induced dermatologic adverse events.Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.A case of successfully treated recalcitrant EGFR inhibitor-induced acneiform eruption following non-ablative fractional laser.Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.Infectious complications associated with monoclonal antibodies and related small moleculesCetuximab in the management of colorectal cancer.Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.The management of EGFR inhibitor adverse events: a case series and treatment paradigm.Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.Skin toxicity of targeted cancer agents: mechanisms and intervention.Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.Targeting the epidermal growth factor receptor in solid tumors: focus on safety.Management of Dermatologic Complications of Lung Cancer Therapies.Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash.Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibitionDermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial).
P2860
Q24187823-86CA714A-7E73-431A-AF90-42599C44F849Q24235777-443897A5-3FA8-4E06-BD56-AD2CE9870769Q26773240-F9F01D51-9CD2-478C-8B93-E8D6AE60E300Q26781472-2CE0E458-7862-4034-81B1-EF60C521037AQ28070095-185EF41B-8B85-4DFB-B1D7-AE882722C3B7Q28081446-08CE3607-A644-4045-BAB8-150AF289F698Q28728031-A7A04F75-ACD6-43CF-B96D-387E4F6692AAQ33683529-42CF90C2-E6CF-4BCF-9F54-D1AB666BBFA7Q33733218-7A92ADB3-DE12-4C0D-BB94-EAE42862691FQ34246558-BE5DE213-824D-46B6-80AC-634F9956A2E3Q34343043-A1D83EDE-30F5-4493-9141-EF0C006A0F84Q35059625-E5D3A794-A6EC-4C0C-A342-B27C5A39949EQ35083960-C7249346-9EC0-4832-9968-AACE818390ECQ35444952-1A0AC9DF-C10D-45C5-AF45-B638C682DB46Q35584416-66CD0C69-7553-4FB9-A503-0B179ADCE8B0Q36008646-C8222BAA-255F-4392-9AB0-B434CDA67184Q36246406-FDC3D00C-64DE-491A-ABB1-B6DE4459737CQ36951089-8E436536-291E-4B41-8690-BA9F12E769AEQ37156636-1EF3CDA1-091D-4C8C-9FF3-6B9A83DF4B65Q37290499-E263ECC7-01EC-4BF0-B3A7-AF8A91635F65Q37390753-8667F6E1-9CB3-4C2F-9305-A1708503D99AQ37442683-25C32D02-EC85-4C8E-873C-22E8CAD0DD42Q37558534-3CC69215-91BE-4871-9E29-8C13499E96D8Q37644848-1F2B15E6-91A6-478D-ADB8-53A7D87E333AQ37780040-D37A6E95-1712-43F5-9D33-747AB11FDC6CQ37829757-A3B9B697-8374-4DC5-879C-838EB5914211Q37976416-F776EBF6-E6B9-4C6A-BAF5-30189526B273Q37987802-E4A8F9C0-5AEB-4F77-A729-5B89D2349BDEQ38005946-9CA669DF-5CD6-4A72-B95E-8438197D3DEAQ38005994-0C059B04-364B-4F79-A502-BAD0D60B31C3Q38083086-64F93BDE-FFC3-4359-B580-54F01E983286Q38125504-0ED5BEC4-DD81-4ECC-9834-4D35645894EBQ38178330-11DCA4C7-B269-4DA7-BBB8-AE818C604FEAQ38200654-9C1A0666-6A79-4D0C-A4E1-B367A72205ABQ38580488-487977CA-1CAC-40D1-889E-2094381C720CQ38961183-E830EA84-4D91-451B-B6E9-D518B592575EQ39034577-D515418F-DF9C-42ED-BF07-29EE04AC2487Q41018872-887190CF-74DF-426D-833E-5C4A0D581989Q41845806-52B614A8-97B9-42BD-B0E4-840580729F92Q42398728-36C87FC5-372A-4604-8CB4-15835FF347C0
P2860
Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cutaneous side effects of epid ...... pathogenesis, and management.
@ast
Cutaneous side effects of epid ...... pathogenesis, and management.
@en
type
label
Cutaneous side effects of epid ...... pathogenesis, and management.
@ast
Cutaneous side effects of epid ...... pathogenesis, and management.
@en
prefLabel
Cutaneous side effects of epid ...... pathogenesis, and management.
@ast
Cutaneous side effects of epid ...... pathogenesis, and management.
@en
P2093
P1476
Cutaneous side effects of epid ...... pathogenesis, and management.
@en
P2093
Jenny C Hu
Lauren C Pinter-Brown
Melvin W Chiu
Parrish Sadeghi
Sharona Yashar
P304
P356
10.1016/J.JAAD.2006.09.005
P407
P577
2006-12-01T00:00:00Z